Soleo Health Selected as a Specialty Pharmacy Partner of ALYGLO™ for Adults With Primary Humoral Immunodeficiency (PI)
16 July 2024 - 10:00PM
Business Wire
Company Selected Based on Its Complex Specialty
Pharmacy Capabilities in Treating Patients with Primary
Immunodeficiency
Soleo Health, an innovative leader and national provider of
complex specialty pharmacy services, announced today it has been
named a limited distribution specialty pharmacy partner for GC
Biopharma USA, Inc. to dispense ALYGLOTM (Immune Globulin
Intravenous, Human-stwk) 10% Liquid for Adults with Primary Humoral
Immunodeficiency (PI).
ALYGLO is a liquid solution containing 10% immunoglobulin G (100
mg/mL) for intravenous infusion, manufactured from pooled human
plasma from U.S. donors. The manufacturing process includes three
steps to reduce the risk of virus transmission. These include
fractionation, solvent/detergent treatment, and nanofiltration.
ALYGLO also uses its novel Cation Exchange Chromatography (CEX) in
the manufacturing process for removing FXIa to undetectable
levels.
Soleo Health is a partner for limited distribution of ALYGLO
based on the company’s deep clinical knowledge and experience in
the provision of immunoglobulin (IG) services and its ability to
collect real-world evidence clinical outcomes through SoleMetrics®,
which is an exclusive and proprietary clinical outcomes program.
SoleMetrics has the distinct ability to collect data specific to
ALYGLO, including details on side effects, adverse events, site of
administration challenges, therapy response and the patient
experience.
"We are pleased to select Soleo Health as a limited distribution
specialty pharmacy for ALYGLO," said Woo Jin Lee, chief executive
officer of GC Biopharma, USA, Inc. "Their proven expertise in
immunoglobulin therapy and dedication to providing an exceptional
patient experience, combined with our mutual goal to ensure that
patients living with primary immunodeficiency have access to this
important treatment, make them an ideal partner."
"Our partnership with GC Biopharma underscores our shared
commitment to enhancing patient care and showcases Soleo Health's
unparalleled expertise in managing patients with complex
conditions. We are honored to be chosen as a partner for ALYGLO,
highlighting our ability to provide individualized patient services
across various care settings," Drew Walk, chief executive officer
of Soleo Health.
For more information about receiving ALYGLO therapy and services
through Soleo Health, contact the Company at phone 844.994.5050,
fax at 844.797.5050 or email IGReferrals@soleohealth.com.
About GC Biopharma USA, Inc.
GC Biopharma USA, Inc., headquartered in Teaneck, NJ,
established its sales, marketing, and business operations in 2018
to serve customers and patients throughout the U.S. Our foundation
is built on the expertise of our parent company, GC Biopharma’s,
expertise - a leading biopharmaceutical company delivering plasma
therapies and vaccines worldwide. With GC Biopharma USA, Inc., GC
Biopharma further extends its footprint, bringing its expertise and
legacy to the United States.
About Soleo Health
Frisco, Texas-based Soleo Health is a leading national provider
of complex specialty pharmacy services administered in the home or
at alternate sites of care. Soleo Health’s interdisciplinary team
comprises highly experienced clinical pharmacists, registered
nurses, reimbursement specialists and patient care ambassadors
collaborating with its referring partners.
The Company optimizes patient access solutions and delivers
comprehensive services, leading to quantifiable clinical and
economic value, resulting in positive patient experiences. Soleo
Health has 26 pharmacy locations with national nursing coverage and
pharmacy licensure in 50 states and is accredited by URAC, ACHC
with Distinction in Rare Disease and Orphan Drugs and The Joint
Commission. Additionally, the Company operates more than 30
infusion centers throughout the U.S.
Visit www.soleohealth.com or connect with Soleo Health on
LinkedIn, Facebook and X for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716121940/en/
For Further Information,
Contact: Susan Turkell, 303.766.4343,
sturkell@soleohealth.com ALYGLO Soleo Therapy Inquiries:
844.994.5050 or IGReferrals@soleohealth.com